Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 79

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 79
---
 2025 is less than 5% of net product sales; majority of this is attributable to Qelbree. Provision for product returns related to prior year sales for the three months period ended March 31, 2024 was less than 1% of net product sales. 

4. Investments 

Marketable SecuritiesUnrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):March 31, 2025December 31, 2024(unaudited)Corporate, U.S. government agency and municipal debt securitiesAmortized cost$347,903 $384,481 Gross unrealized gains12 89 Gross unrealized losses(173)(289)Total fair value$347,742 $384,281  As of March 31, 2025, all of our unrestricted available-for-sale marketable securities have contractual maturities of one year or less.

As of March 31, 2025, there was no impairment due to credit loss on any available-for-sale marketable securities. 

5.    Fair Value of Financial Instruments

The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels: 

10

•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets. •Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves). •Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data. Financial Assets and Liabilities Recorded at Fair ValueThe Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):Fair Value Measurements as of March 31, 2025 (unaudited) TotalLevel 1 Level 2Level 3Assets:Cash and cash equivalentsCash$28